Nir Naor - 19 Jun 2023 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Director
Issuer ticker: BCLI
Reported as of: 19 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2023, 16:06:43 UTC
Next SEC filing: 04 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Nir Naor

Key filing fact

Nir Naor filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 21 Jun 2023.

Key facts

This page summarizes Nir Naor's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Jun 2023, 16:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value: $0
Shares: +11,999
Change %
Price: $0.000000
Shares after: 11,999
Date: 19 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares acquired are shares of restricted stock awarded on June 19, 2023 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on June 19, 2023 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics Inc. on each vesting date.